1. Home
  2. DRMA
  3. DRMA News

Latest Dermata Therapeutics Inc. (DRMA) News on April 25, 2025

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
DRMA

ACCESS Newswire

10 days ago

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
DRMA

ACCESS Newswire

a month ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
DRMA

PR Newswire

a month ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
DRMA

ACCESS Newswire

a month ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
DRMA

PR Newswire

2 months ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
DRMA

ACCESS Newswire

2 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025
DRMA

ACCESS Newswire

3 months ago

Dermata to Present on BioPub on January 31, 2025

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DRMA

ACCESS Newswire

3 months ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DRMA

ACCESS Newswire

3 months ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DRMA

MT Newswires

3 months ago

Dermata, Revance Collaborate on Trial to Treat Chronic Armpit Sweating

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
DRMA

ACCESS Newswire

3 months ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
DRMA

ACCESSWIRE

4 months ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
DRMA

ACCESSWIRE

4 months ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
DRMA

ACCESSWIRE

5 months ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Life Sciences Investor Forum: Presentations Now Available for Online Viewing
DRMA

GlobeNewswire

5 months ago

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
DRMA

ACCESSWIRE

5 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Life Sciences Investor Forum Agenda Announced for November 14th
DRMA

GlobeNewswire

5 months ago

Life Sciences Investor Forum Agenda Announced for November 14th

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
DRMA

GlobeNewswire

5 months ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
DRMA

ACCESSWIRE

7 months ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DRMA

ACCESSWIRE

7 months ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DRMA

MT Newswires

7 months ago

Top Premarket Decliners

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DRMA

ACCESSWIRE

7 months ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DRMA

MT Newswires

7 months ago

Top Premarket Gainers

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
DRMA

ACCESSWIRE

8 months ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
DRMA

ACCESSWIRE

9 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
DRMA

ACCESSWIRE

9 months ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
DRMA

ACCESSWIRE

a year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
DRMA

ACCESSWIRE

a year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
DRMA

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

Dermata to Present at the Emerging Growth Conference on April 3, 2024
DRMA

ACCESSWIRE

a year ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
DRMA

ACCESSWIRE

a year ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
DRMA

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now

Dermata to Present at the Emerging Growth Conference on February 7, 2024
DRMA

ACCESSWIRE

a year ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Launching our most comprehensive test and expanding into new global markets
DRMA

GlobeNewswire

a year ago

Launching our most comprehensive test and expanding into new global markets

Singularity Future Technology Announces 1-for-10 Reverse Stock Split
DRMA

GlobeNewswire

a year ago

Singularity Future Technology Announces 1-for-10 Reverse Stock Split

Davis Commodities Limited Releases 2024 Chairwoman Letter to Shareholders
DRMA

GlobeNewswire

a year ago

Davis Commodities Limited Releases 2024 Chairwoman Letter to Shareholders

Megawatt grants electrify truck charging corridors
DRMA

FreightWaves

a year ago

Megawatt grants electrify truck charging corridors

Sidoti Events, LLC's Virtual January Micro-Cap Conference
DRMA

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Actelis Announces U.S. Department of Defense JITC Labs Approval for Cybersecurity and Interoperability and Approved Products List Status
DRMA

GlobeNewswire

a year ago

Actelis Announces U.S. Department of Defense JITC Labs Approval for Cybersecurity and Interoperability and Approved Products List Status

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
DRMA

Zacks

a year ago

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
DRMA

GlobeNewswire

a year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

ZK International Group Co., Ltd. Embarks on Global Expansion: Enters Southeast Asia and the Middle East to Drive Innovation and Sustainable Infrastructure Development
DRMA

PR Newswire

a year ago

ZK International Group Co., Ltd. Embarks on Global Expansion: Enters Southeast Asia and the Middle East to Drive Innovation and Sustainable Infrastructure Development

Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now
DRMA

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now

Addex to Present at Biotech Showcase™ 2024
DRMA

GlobeNewswire

a year ago

Addex to Present at Biotech Showcase™ 2024

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
DRMA

ACCESSWIRE

a year ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
DRMA

GlobeNewswire

a year ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Velo3D, Inc. Receives Continued Listing Standards Notice from the NYSE
DRMA

Business Wire

a year ago

Velo3D, Inc. Receives Continued Listing Standards Notice from the NYSE

Hall of Fame Resort & Entertainment Company Partners with Josh Harris and David Blitzer to Elevate Youth Sports at Hall of Fame Village
DRMA

PR Newswire

a year ago

Hall of Fame Resort & Entertainment Company Partners with Josh Harris and David Blitzer to Elevate Youth Sports at Hall of Fame Village

Tandy Leather Factory (NASDAQ:TLF) Has Some Difficulty Using Its Capital Effectively
DRMA

Simply Wall St.

a year ago

Tandy Leather Factory (NASDAQ:TLF) Has Some Difficulty Using Its Capital Effectively

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
DRMA

ACCESSWIRE

a year ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

IZEA Announces its Headline Sponsorship of Creator Economy Live 2024
DRMA

GlobeNewswire

a year ago

IZEA Announces its Headline Sponsorship of Creator Economy Live 2024

Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US
DRMA

GlobeNewswire

a year ago

Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US

DRMA

GlobeNewswire

a year ago

Society Pass Inc. (Nasdaq: SOPA)/Thoughtful Media Group Inc (TMG): Greenridge Global Initiates Equity Research Coverage on TMG; TMG To Capture Significant Advertising Market Share In Southeast Asia

Movano Health Announces Blood Pressure Partnership Forum Following Significant Response to Groundbreaking Accuracy Achievement
DRMA

PR Newswire

a year ago

Movano Health Announces Blood Pressure Partnership Forum Following Significant Response to Groundbreaking Accuracy Achievement

DRMA

GlobeNewswire

a year ago

Bit Origin Ltd Secures $6.74 Million Investment to Build a New Crypto Mining Data Center in the U.S.

DRMA

GlobeNewswire

a year ago

Society Pass Inc (Nasdaq: SOPA): Ascendiant Capital Issues 3Q 2023 Equity Research Update; 3Q Results Show Solid Revenue Growth and Maintains Positive Outlook on Growth Prospects

Uxin Limited Announces Successful Validation of Superstore Business Model, Significant Reduction in Losses, and Target of Achieving Overall Profitability by 2024
DRMA

PR Newswire

a year ago

Uxin Limited Announces Successful Validation of Superstore Business Model, Significant Reduction in Losses, and Target of Achieving Overall Profitability by 2024

Sidoti Events, LLC's Virtual December Small-Cap Conference
DRMA

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

NeuroStar TMS Receives Expanded Regulatory Approval in Japan
DRMA

GlobeNewswire

a year ago

NeuroStar TMS Receives Expanded Regulatory Approval in Japan

Vision Marine Technologies Initiates First E-Motion(TM) Equipped Rental Operation Expansion in Florida in Partnership with Blue Water Boat Rental
DRMA

ACCESSWIRE

a year ago

Vision Marine Technologies Initiates First E-Motion(TM) Equipped Rental Operation Expansion in Florida in Partnership with Blue Water Boat Rental

Farmmi Ships Latest Order to Canada; Company Continues to Benefit from Healthy North American Demand
DRMA

PR Newswire

a year ago

Farmmi Ships Latest Order to Canada; Company Continues to Benefit from Healthy North American Demand

Hundreds of Stocks Have Fallen Below $1. They’re Still Listed on Nasdaq.
DRMA

The Wall Street Journal

a year ago

Hundreds of Stocks Have Fallen Below $1. They’re Still Listed on Nasdaq.

Investors in Neuronetics (NASDAQ:STIM) from five years ago are still down 90%, even after 40% gain this past week
DRMA

Simply Wall St.

a year ago

Investors in Neuronetics (NASDAQ:STIM) from five years ago are still down 90%, even after 40% gain this past week

Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
DRMA

PR Newswire

a year ago

Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®

Maison Solutions Closes Private Placement
DRMA

ACCESSWIRE

a year ago

Maison Solutions Closes Private Placement

DRMA

GlobeNewswire

a year ago

Bit Origin Ltd Announces New Financing and Provides Business Plan Update

MSSP Alert Names CISO Global to 2023 Top 250 Managed Security Services Providers List
DRMA

GlobeNewswire

a year ago

MSSP Alert Names CISO Global to 2023 Top 250 Managed Security Services Providers List

Downgrade: What You Need To Know About The Latest Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Forecasts
DRMA

Simply Wall St.

a year ago

Downgrade: What You Need To Know About The Latest Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Forecasts

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
DRMA

Zacks

a year ago

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug

Regional Health Properties Reports Third Quarter 2023 Financial Results
DRMA

GlobeNewswire

a year ago

Regional Health Properties Reports Third Quarter 2023 Financial Results

Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
DRMA

Simply Wall St.

a year ago

Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
DRMA

ACCESSWIRE

a year ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

DRMA

Zacks Small Cap Research

a year ago

AEMD: Expect Focus on Oncology Studies; Cost Containment Efforts

Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript
DRMA

Insider Monkey

a year ago

Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript

Lightbridge CEO Seth Grae Interviewed on Scripps News TV
DRMA

GlobeNewswire

a year ago

Lightbridge CEO Seth Grae Interviewed on Scripps News TV

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
DRMA

ACCESSWIRE

a year ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Moving iMage Technologies, Inc. (AMEX:MITQ) Q1 2024 Earnings Call Transcript
DRMA

Insider Monkey

a year ago

Moving iMage Technologies, Inc. (AMEX:MITQ) Q1 2024 Earnings Call Transcript

When Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?
DRMA

Simply Wall St.

a year ago

When Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?

ClearSign Technologies Corporation Provides Third Quarter 2023 Update
DRMA

PR Newswire

a year ago

ClearSign Technologies Corporation Provides Third Quarter 2023 Update

NextPlat Reports Consolidated Third Quarter 2023 Results with Increased Revenues of $15.3 Million, Margins Improve to 30% and $2.7 Million Net Income
DRMA

PR Newswire

a year ago

NextPlat Reports Consolidated Third Quarter 2023 Results with Increased Revenues of $15.3 Million, Margins Improve to 30% and $2.7 Million Net Income

U.S. Energy Corp. Reports Financial and Operating Results for Third Quarter 2023
DRMA

GlobeNewswire

a year ago

U.S. Energy Corp. Reports Financial and Operating Results for Third Quarter 2023

Can AEye (NASDAQ:LIDR) Afford To Invest In Growth?
DRMA

Simply Wall St.

a year ago

Can AEye (NASDAQ:LIDR) Afford To Invest In Growth?

DRMA

Thomson Reuters StreetEvents

a year ago

Q3 2023 Superior Drilling Products Inc Earnings Call

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
DRMA

ACCESSWIRE

a year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Superior Drilling Products Reports Third Quarter 2023 Results
DRMA

Business Wire

a year ago

Superior Drilling Products Reports Third Quarter 2023 Results

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
DRMA

GlobeNewswire

a year ago

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

ClearSign Technologies Corporation Announces Hire of Matthew Martin as Chief Technology Officer
DRMA

PR Newswire

a year ago

ClearSign Technologies Corporation Announces Hire of Matthew Martin as Chief Technology Officer

DRMA

Associated Press Finance

a year ago

Gold Resource: Q3 Earnings Snapshot

Gold Resource Corporation Reports Third Quarter Operational Results and Announces the Initiation of a Review to Evaluate Strategic Alternatives
DRMA

Business Wire

a year ago

Gold Resource Corporation Reports Third Quarter Operational Results and Announces the Initiation of a Review to Evaluate Strategic Alternatives

Energous Corporation Announces Conference Call for Third Quarter 2023 Financial Results
DRMA

Business Wire

a year ago

Energous Corporation Announces Conference Call for Third Quarter 2023 Financial Results

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
DRMA

GlobeNewswire

a year ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Share on Social Networks: